Evidence map›Paper›PMID 33597993›Full record

ArticlePostepy w kardiologii interwencyjnej = Advances in interventional cardiology2020

Altered microRNA dynamics in acute coronary syndrome.

Kazimierczyk Ewelina, Andrzej Eljaszewicz, Remigiusz Kazimierczyk, Marlena Tynecka, Paula Zembko, Ewa Tarasiuk, Karol Kaminski, Bozena Sobkowicz, Marcin Moniuszko, Agnieszka Tycinska

Open access · goldAbstract read
In one paragraph

Article in Postepy w kardiologii interwencyjnej = Advances in interventional cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. MicroRNA-1: Diverse role of a small player in multiple cancers.Seminars in cell & developmental biology · 2022
    Review
  7. Review
  8. Upregulation of Serum miRNA-3615 Serves as a Biomarker to Predict Disease Onset and Prognosis in Acute Coronary Syndrome Patients.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Kazimierczyk EwelinaDepartment of Cardiology, Medical University of Bialystok, Bialystok, Poland.
Andrzej EljaszewiczDepartment of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland.
Remigiusz KazimierczykDepartment of Cardiology, Medical University of Bialystok, Bialystok, Poland.
Marlena TyneckaDepartment of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland.
Paula ZembkoDepartment of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland.
Ewa TarasiukDepartment of Cardiology, Medical University of Bialystok, Bialystok, Poland.
Karol KaminskiDepartment of Cardiology, Medical University of Bialystok, Bialystok, Poland.
Bozena SobkowiczDepartment of Cardiology, Medical University of Bialystok, Bialystok, Poland.
Marcin MoniuszkoDepartment of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland.
Agnieszka TycinskaDepartment of Cardiology, Medical University of Bialystok, Bialystok, Poland.
Medical University of Białystok · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn the course of acute myocardial infarction (AMI) cardiomyocyte injury, activation and destruction of endothelial cells together with inflammation lead to miRNA expression alterations.

aimTo assess levels of circulating cardiac-specific (miR-1) and endothelial-specific (miR-126) miRNAs in the acute phase of AMI and after a follow-up period. MATERIAL AND

methodsSeventeen AMI patients (mean age: 64.24 ±13.83 years, mean left ventricle ejection fraction (LVEF): 42.6 ±9.65%), treated with primary percutaneous coronary intervention within the first 12 h, had plasma miRNAs isolated (quantitative real-time PCR, Exiqon) on admission and after 19.2 ±5.9 weeks. Measurements were also performed in a control group of healthy volunteers matched for age and sex.

resultsConcentrations of both miRNAs were significantly higher in AMI patients as compared to healthy controls: miR-1: 5.93 (3.15-14.92) vs. 1.46 (0.06-2.96),

conclusionsIn our study, miR-1 emerged as a marker of cardiomyocyte injury and loss of myocardial contractility, whereas dynamics of miR-126 concentration may reflect endothelial activation and damage in the most extreme stage of atherosclerosis, followed by angiogenesis in ischemic myocardium. However, to fully elucidate the role of miR-1 and miR-126 as biomarkers of AMI and future therapeutic targets, further research is required.

Indexed as

microRNAmiR-1miR-126myocardial infarction

Identifiers

PMID33597993
PMCPMC7863810
OpenAlexW3096165084

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.